Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03719898
Title Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Fox Chase Cancer Center
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Fox Chase Cancer Center Philadelphia Pennsylvania 19011 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field